Ticlopidine
- Generic Name
- Ticlopidine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14ClNS
- CAS Number
- 55142-85-3
- Unique Ingredient Identifier
- OM90ZUW7M1
- Background
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has...
- Indication
Used in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
- Associated Conditions
- Stroke, Thrombosis (Stent Thrombosis), Thrombotic Stroke, Subacute stent thrombosis
- Associated Therapies
- -
A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT03298906
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
- Conditions
- Interventions
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01214941
- Locations
- 🇫🇮
Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital, Turku, Finland
Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease
- Conditions
- Interventions
- First Posted Date
- 2009-03-16
- Last Posted Date
- 2012-07-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 431
- Registration Number
- NCT00862420
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1003
- Registration Number
- NCT00821834
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Antiplatelet Therapy to Prevent Stroke in African Americans
- Conditions
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.